Company Overview
| Stock Name | C-Mer Medical |
|---|---|
| Stock Code | 03309 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是香港及廣東省領先的眼科服務提供商之一,提供白內障、眼角膜與眼表疾病、青光眼、玻璃體視網膜及黃斑疾病等眼科疾病的診斷與治療服務,以及針灸及中醫輔助治療眼疾。 |
| Listing Date | 2018-01-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港畢打街1-3號中建大廈1535室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | cmereye.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 2.90 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2017-12-29 to 2018-01-08 |
| Global Offering Shares | 197,000,000 shares |
| HK Public Offer Shares (Initial) | 19,700,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 177,300,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,000,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 36.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 571,300,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.33B |
| Est. Threshold | HK$ 9.44B |
| Analysis Result | HK market cap below threshold, need +611% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 2,630,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | 約1,700百萬港元 |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 2016年盈利約46.9百萬港元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 50,000,000 |
| Listing Expenses / Funds Raised | ~8.75% |
| Total Pre-IPO Investment | 142.0百萬港元 |
Financial Data
Unit:
'000
HKD
Income Statement
| Item | 2014 | 2015 | 2016 | 2017-06 |
|---|---|---|---|---|
| Revenue | 156,472 | 198,851 | 248,659 | 140,449 |
| Cost of sales | -97,429 | -119,150 | -153,683 | -77,755 |
| Gross profit | 59,043 | 79,701 | 94,976 | 62,694 |
| Other income and gains, net | 201 | 547 | 1,497 | 678 |
| Selling and distribution expenses | -2,918 | -4,694 | -7,874 | -4,235 |
| Administrative expenses | -27,676 | -26,454 | -30,534 | -24,806 |
| Operating profit | 28,929 | 49,620 | 59,528 | 34,617 |
| Net finance costs | -966 | -1,189 | -932 | -334 |
| Profit before tax | 27,963 | 48,431 | 58,596 | 34,283 |
| Income tax expense | -5,602 | -10,074 | -11,709 | -8,927 |
| Profit for the year | 22,361 | 38,357 | 46,887 | 25,356 |
| Profit attributable to owners | 22,361 | 38,357 | 46,887 | 25,356 |
Balance Sheet
| Item | 2014 | 2015 | 2016 | 2017-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 11,246 | 23,348 | 58,760 | 182,229 |
| Trade and bills receivables | 1,745 | 3,464 | 4,456 | 6,095 |
| Inventories | 2,021 | 1,507 | 2,328 | 2,366 |
| Total current assets | 52,919 | 90,551 | 85,890 | 244,222 |
| Total assets | 102,817 | 132,375 | 128,642 | 311,728 |
| Total current liabilities | 64,733 | 58,464 | 64,024 | 75,888 |
| Total liabilities | 72,004 | 65,427 | 65,210 | 76,820 |
| Total equity | 30,813 | 66,948 | 63,432 | 234,908 |
| Equity attributable to owners | 30,813 | 66,948 | 63,432 | 234,908 |
| Interest-bearing borrowings | 43,884 | 33,310 | 18,523 | 19,502 |
Cash Flow Statement
| Item | 2014 | 2015 | 2016 | 2017-06 |
|---|---|---|---|---|
| Net cash from operating activities | 42,606 | 50,545 | 53,497 | 34,425 |
| Net cash from investing activities | -28,372 | -25,739 | -13,821 | -47,856 |
| Net cash from financing activities | -6,112 | -13,007 | -3,048 | 135,698 |
| Net increase in cash | 8,122 | 11,799 | 36,628 | 122,267 |
| Purchase of PP&E | -7,342 | -2,699 | -11,247 | -1,869 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 5.11 |
|---|---|
| First Day Open | HK$ 5.35 |
| First Day Change | 76.21% |
| First Day Volume | 211598000.0 |
| First Day Turnover | 1120740000.0 |
| Use of Proceeds | 1、221.6百萬港元(或42.5%)用于對選定中國城市三間運營中眼科醫院的潛在收購;
2、210.6百萬港元(或40.4%)用于在選定的中國城市開設三間眼科醫院;
3、21.9百萬港元(或4.2%)用于在中國深圳開設兩間衛星診所;
4、44.3百萬港元(或8.5%)用于升級我們的醫療設備及強化我們在香港及中國的信息科技系統;
5、22.9百萬港元(或4.4%)用于我們的營運資金及一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Overall Coordinators (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Bookrunners (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Advance Data Services Limited | 68,805,400 HKD | — | 12.00% | — | 6 months | 2018-07-15 |
| 2 | Gunther Group Limited | 68,805,400 HKD | — | 12.00% | — | 6 months | 2018-07-15 |
| 3 | 香港华丽有限公司 | 68,805,400 HKD | — | 12.00% | — | 6 months | 2018-07-15 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 林順潮 | — |
| Company Secretary | 陳華平 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 希瑪集團、林順潮及李肖婷為控股股東;緊隨全球發售及資本化發行完成後,希瑪集團持有722,696,756股股份,佔72.3%。 |
|---|




